WARN : Please note that some of the values may not be in base currency

Fundamental Analysis of Kazia Therapeutics Ltd ADR - Growth / Value Index


KZIA - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Very Poor Score of 12.50
   Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -2.91 -3.26 -2048.72 %
Price to Book 3.78 5.53 2659.41 % 1.28
Price to Sales 81318.48 120168 -19.64 %
Enterprise Value to EBITDA Multiple -0.228 -2.62 -3776.98 %


KZIA - Profitability Highlights

Profitability Analysis

   Excellent QoQ /QoQ FY EPS growth
   Reasonable Dividend Yield of 3.77 %
   Tsr Profitability Index - Very Poor Score of 5.00
   Piotroski F Score - Very Poor Value of 2.0
   Negative Net profit for last two years
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
   Negative Net Margin MRQ
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity -149.45 -169.83 -28.42 % -167.51
Return On Asset -57.64 -72.87 -3.35 % -36.19
Net Profit Margin -2799049.02 -3687419.82 96.26 % -176470260.00
Operating Profit Margin -3456942.07 -4350825.59 95.97 % -177668060.00
EBITDA Margin -3123711.59 -4350825.59 95.65 % -158973960.00


Highlights
Market Cap7439.22 K
Enterprise Value3994.52 K
Price/Book TTM3.78
Outstanding Share26361.50 K
Float/ Outstanding Share899.88%
Dividend Yield3.77 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score2.00
Altman Z Score-7.08
Sloan Ratio-0.189
Peter Lynch Fair Value0


KZIA - Growth Highlights

Growth Analysis

   STRONG JUMP IN NET SALE : YoY growth
   Tsr Growth Index - Poor Score of 22.71
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 561.00 2120.00 % 98.20 %
Gross Profit 561.00 2120.00 % 98.20 %
EBITDA -17524.02 K 3.46 % 66.02 %
Net Profit -15702.67 K 16.97 % 156.53 %
EPS -0.097 95.35 % NA


KZIA - Stability Highlights

Stability Analysis

   Altman Z Score of -7.07 suggest high risk
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of 0
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.149 50.93 % 0.068
Cash Ratio 0.693 -55.91 %
Quick Ratio 1.44 0 % 0.712
Shareholders Equity 42.91 -19.52 %
Debt to EBITDA -0.074 -1.09 %


Historical Valuation Ratios of Kazia Therapeutics Ltd ADR

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Kazia Therapeutics Ltd ADR

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Kazia Therapeutics Ltd ADR

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Kazia Therapeutics Ltd ADR

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)